Analytical Data
-
Gene name
WDR33
- Application
-
Alternative Names
WD repeat containing Protein 33; WD repeat domain 33; WD repeat-containing Protein 33; WD repeat-containing Protein WDC146; WDC146; WDR 33; WDR33; WDR33_HUMAN
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9C0J8
-
Expression Region
1-326 aa
-
AA Sequence
MATEIGSPPRFFHMPRFQHQAPRQLFYKRPDFAQQQAMQQLTFDGKRMRKAVNRKTIDYNPSVIKYLENRIWQRDQRDMRAIQPDAGYYNDLVPPIGMLNNPMNAVTTKFVRTSTNKVKCPVFVVRWTPEGRRLVTGASSGEFTLWNGLTFNFETILQAHDSPVRAMTWSHNDMWMLTADHGGYVKYWQSNMNNVKMFQAHKEAIREARFIHNIPFSVVPIVMVKLFSKCILGAEMHGLCQFLGNFLHPINTIFFFVFTHSPFCWHLSEVVLSRYQPLQYVRDVLSAAFCTGFLFSFMINNVYTLFLFIIYCVRQEYFIPNKEFSL
-
Molecular Weight
64.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
WDR33, or WD-repeat domain 33, is a protein that plays a pivotal role in various cellular processes, particularly in RNA metabolism and the regulation of gene expression. Research has increasingly focused on WDR33 due to its involvement in the mammalian spliceosomal machinery, where it is thought to participate in pre-mRNA splicing. Mutations or dysregulation of WDR33 have been associated with several diseases, including certain types of cancer and genetic disorders, highlighting its potential as a therapeutic target. The study of WDR33's structure and function is essential for understanding the molecular mechanisms underlying these conditions. Recent advancements in protein engineering and reconstitution techniques have allowed scientists to create WDR33 recombinant proteins, facilitating in-depth functional analyses and biophysical characterization. These studies aim to elucidate WDR33's role in splicing regulation and its interactions with other spliceosomal components, thereby providing insights into its contribution to cellular homeostasis and disease pathology. By studying WDR33, researchers hope to uncover novel regulatory pathways and therapeutic strategies, reinforcing the importance of this protein in both fundamental biology and clinical applications.
